Pembrolizumab: A novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma

Journal of Clinical Pharmacy and Therapeutics

Volumn 40, Issue 5, 2015, Pages 504-507

  Tan, M ^a   Quintal, L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

checkpoint; monoclonal antibody; systematic review

Indexed keywords

CREATINE KINASE; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR;

ABNORMAL LABORATORY RESULT; ADRENAL INSUFFICIENCY; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CHILL; COHORT ANALYSIS; COLITIS; DIARRHEA; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ECONOMIC ASPECT; FATIGUE; FEVER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEADACHE; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPERTRANSAMINASEMIA; HYPOPHYSITIS; HYPOTHYROIDISM; IMMUNOPATHOLOGY; KIDNEY CARCINOMA; KIDNEY FAILURE; MEDICAL LITERATURE; MERKEL CELL TUMOR; METASTATIC MELANOMA; MULTIPLE MYELOMA; MYALGIA; MYCOSIS; NERVOUS SYSTEM INFLAMMATION; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; REVIEW; RHABDOMYOLYSIS; SEZARY SYNDROME; SURVIVAL RATE; SYSTEMATIC REVIEW; TRANSITIONAL CELL CARCINOMA; TREATMENT INDICATION;

EID: 84941024718     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12304     Document Type: Review

References (28)

1. Siegel R, Ma J, Zou Z, et al,. Cancer statistics, 2014. CA Cancer J Clin, 2014; 64: 9-29.
2. National Comprehensive Cancer Network. Melanoma. Version 1.2015. National Comprehensive Cancer Network website. Available at: http://www.nccn.org/professionals/physician-gls/PDF/melanoma.pdf (accessed 12 December 2014).
3. Chapman PB, Hauschild A, Robert C, et al,. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med, 2011; 364: 2507-2516.
4. Hauschild A, Grob JJ, Demidov LV, et al,. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet, 2012; 380: 358-365.
5. Flaherty KT, Robert C, Hersey P, et al,. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med, 2012; 367: 107-114.
6. Hodi FS, O'Day SJ, McDermott DF, et al,. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 2010; 363: 711-723.
7. Merck & Co., Inc. Pembrolizumab (package insert). Whitehouse Station, NJ: Merck & Co, Inc, 2014.
8. U. S. Food and Drug Administration. FDA approves Keytruda for advanced melanoma: first PD-1 blocking drug to receive agency approval. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm (accessed 12 December 2014).
9. Vesely MD, Kershaw MH, Schreiber RD, et al,. Natural innate and adaptive immunity to cancer. Annu Rev Immunol, 2011; 29: 235-271.
10. Seliger B,. Strategies of tumor immune evasion. BioDrugs, 2005; 19: 347-354.
11. Freeman GJ, Long AJ, Iwai Y, et al,. Engagement of the PD-1 Immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med, 2000; 192: 1027-1034.
12. Mamalis M, Garcha M,. Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res, 2014; 206: 511-519.
13. Hargadon KM,. Melanoma immunotherapy: overcoming obstacles to augment anti-tumor immune responses. J Cosmet Dermatol Sci Appl, 2013; 3: 7-27.
14. Chapon M, Randriamampita C, Maubec E, et al,. Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes. J Investig Dermatol, 2011; 131: 1300-1307.
15. Bayer HealthCare Pharmaceuticals. Aldesleukin (package insert). Emeryville, CA: Bayer HealthCare Pharmaceuticals, 2012.
16. Bristol-Myers Squibb Company. Ipilimumab (package insert). Princeton, NK: Bristol-Myers Squibb Company, 2013.
17. Okazaki T, Chikuma S, Iwai Y, et al,. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol, 2013; 14: 1212-1218.
18. Iwai Y, Ishida M, Tanaka Y, et al,. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. PNAS, 2002; 99: 12293-12297.
19. Blank C, Gajewski TF, Mackensen A,. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother, 2005; 54: 307-314.
20. Robert C, Ribas A, Wolchok JD, et al,. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomized dose-comparison cohort of a phase 1 trial. Lancet, 2014; 384: 1109-1117.
21. Hamid O, Robert C, Daud A, et al,. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med, 2013; 369: 134-144.
22. U. S. National Institutes of Health. Clinical trials. Available at: http://clinicaltrials.gov (accessed 12 December 2014).
23. Min L, Hodi FS,. Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res, 2013; 2: 15-18.
24. Mandel JJ, Olar A, Aldape KD, et al,. Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci, 2014; 344: 229-231.
25. Bristol-Myers Squibb. Nivolumab (package insert). Princeton, NJ: Bristol-Myers Squibb, 2014.
26. U. S. Food and drug administration. FDA approves Opdivo for advanced melanoma. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427716.htm (accessed 26 December 2014).
27. Wolchok JD, Kluger H, Callahan MK, et al,. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med, 2013; 369: 122-133.
28. LexiComp. Pembrolizumab. Available at: http://online.lexi.com (2014, accessed 12 December 2014).